Scientific Sessions 2024  /  Disrupting the Status Quo: Aldosterone Dysregulation in ​the Pathogenesis of Hypertension  /  Disrupting the Status Quo: Aldosterone Dysregulation in the Pathogenesis of Hypertension

American Heart Association

  66
  0

Final ID:

Disrupting the Status Quo: Aldosterone Dysregulation in the Pathogenesis of Hypertension

  • Xlaffinx, Xlukex  ( Cleveland Clinic Foundation , Cleveland , Ohio , United States )
    • Author Disclosures:
    xLukex xLaffinx: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Consultant:Crispr Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead Pharmaceuticals:Active (exists now) ; Consultant:Idorsia:Active (exists now) ; Consultant:Veradermics:Active (exists now) ; Advisor:Gordy Health:Past (completed) ; Advisor:LucidAct Health:Past (completed) ; Research Funding (PI or named investigator):Mineralys:Active (exists now) ; Research Funding (PI or named investigator):Astrazeneca:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Speaker:Recor:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Disrupting the Status Quo: Aldosterone Dysregulation in ​the Pathogenesis of Hypertension

Saturday, 11/16/2024 , 11:15AM - 12:00PM

Heart Theater

More abstracts from these authors:
Prevalence of Familial Hypercholesteremia (FH) Among Participants in the ACCELERATE Trial: Implications for Opportunistic FH Screening and Prognostication

Sarraju Ashish, St John Julie, Singh Abhayjit, Knowles Josh, Rodriguez Fatima, Bruemmer Dennis, Cho Leslie, Xlaffinx Xlukex

Association of Blood Pressure Time in Target Range with Outcomes Among NIH "All of Us” Cohort

Agarwal Neel, St John Julie, Xlaffinx Xlukex

You have to be authorized to contact abstract author. Please, Login
Not Available